Full Length Research Paper

A prospective study on assessment of clinically potential drug-drug interactions in hospital and community pharmacy prescriptions

Clement Kabakama¹, Rangadham Pydimarri² and Sivasankaran Ponnusankar²

¹Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Tanzania.
²Department of Pharmacy Practice, JSS Academy of Higher Education and Research, India.

Received 7 December, 2020; Accepted 4 May, 2021

Drug-drug interaction or simply term drug interactions may be defined as the combining of two or more drugs such that the potency or efficiency of one drug is significantly modified by the presence of another. Potential drug-drug interactions (DDIs) are concern for patients and providers, as multiple medication use is becoming more common to manage complex diseases. The consequences of DDIs can range from no untoward effects to drug-related morbidity and mortality. The study was prospective conducted for a period of twelve months in Government Headquarters Hospital Ooty (GHQH) and four community pharmacies that were located in Southern India, Tamilnadu. A total number of 1,066 prescriptions were collected from the patients. A copy of prescription was taken from the patients and data collected included age and sex of the patients, their primary diagnoses presence or absence of comorbidities and the list of medications prescribed concurrently. The potential DDIs were determined through IBM Micromedex Database. However, 147 DDIs were followed up for clinically drug interactions which were found not to be significant. Among the total numbers of prescriptions analyzed 402 (38%) prescriptions showed 462 DDIs and 664 (62.2%) total number of prescriptions collected from inpatient department, GHQH showed 147 DDIs. The DDIs were classified based on the mechanism of interactions, severity of interactions, drug causing DDIs and top combination of drugs and which were determined. This study emphasized on understanding about the most prone age group and the common mechanism that can cause drug interactions which will help in the safety and efficacy of prescribed drugs followed by its management.

Key words: Drug-Drug interactions, prescriptions, prevalence, severity, management.

INTRODUCTION

Drug-drug interactions (DDIs) are defined as the presence of two or more drugs where one drug significantly modifies the action of another drug (Bruno et al, 2007; Jindal et al., (2005) and Janchawee et al., 2005). This is a major concern for patients and healt care professionals as most of the diseases require multiple drug regimen. The consequences of DDIs can range from untoward effects to drug-related morbidity (Vonbach et al., 2007; Lubinga et al., (2011) and David et al., 2003) and mortality. Understanding the prevalence and patients

*Corresponding author. E-mail: ceykam@yahoo.com, Telephone number +255784935939.

Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License
At risk for clinically important DDIs at the visit level will be useful in minimizing medication-related problems and improving pharmaceutical care (Kennedy et al., 2015). Previous research has found that drug-drug interactions (potential DDIs) lead to adverse clinical outcomes, hospital admissions and emergency department (ED) visits. Health care professionals’ ability to recognize potential DDIs is important in reducing the risk of potential DDIs and their adverse consequences. The consequences of DDIs can range from untoward effects to drug-related morbidity and mortality. Understanding the prevalence and patients at risk for clinically important DDIs at the visit level will be useful in minimizing medication-related problems and improving pharmaceutical care (Jorg et al. 2007), (Mitja 2017). Previous research has found that drug-drug interactions (potential DDIs) lead to adverse clinical outcomes, hospital admissions and emergency department (ED) visits.

Health care professionals’ ability to recognize potential DDIs is important in reducing the risk of potential DDIs and their adverse consequences (Malone et al., 2005), Elena et al. (2013), Janja et al., (2017). The potential benefits of drug combinations should be weighed against the seriousness of the DDI, taking into account the availability of alternatives. The risk associated with the drug-drug interactions are higher, hence alternative drug should be prescribed as to avoid potential DDI (Kausalikabai et al., 2016) and Walter et al., (2007).

Understanding the prevalence and clinically DDIs at hospital level will be minimized and improving overall pharmaceutical care (Becker and Kallewaard, 2007). According to a study, the odds ratio of having at least one drug interaction, the rate of the drug interaction was the same for both genders when age was increased by 20 years (Rajender et al., 2007). The objectives of this study were to find out prevalence of potential DDIs among the collected hospital prescriptions and the community pharmacy prescriptions, and to categorize the identified interactions as to assess its severity, mechanisms involved and its management requirements.

Exclusion criteria
Patients prescribed with a single medication and patients prescribed with the topical formulations such as a creams, ointments, and gels.

Ethics
The study was approved by Institution Ethical Committee of JSS Academy of Higher Education and Research (Approval number: JSSAHER/OT/IEC/07/2017-18 Dated (06/01/2018).

Data extraction
The collected data was taken from patient's prescription and each prescription was analyzed and checked for potential DDI through Micromedex IBM data base, assessment and categorization of the interaction was found with the indication as per the Classification on Micromedex termed Contraindication. The drugs were contraindicated for concurrent use. Major 1: The interaction may be life threatening and/or require medical intervention to minimize or prevent serious adverse effects. Major 2: The interaction may be life threatening and/or require medical intervention to minimize or prevent serious adverse effects. Moderate: The interaction may result in exacerbation of the patient’s condition and/or require an alteration in therapy. Minor: The interaction would have limited clinical effects. Manifestation may include an increase in frequency or severity of the side effects but generally would not require a major alteration in therapy. Unknown (Truven Health Analytics, 2016).

RESULTS
A total of 1,066 prescriptions were analyzed during the study period which was collected from Government Headquarters Hospital Ooty (GHQH) and from the four community pharmacies. Among the total numbers of prescriptions analyzed, 402 (38%) prescriptions showed 462 DDIs and 664 (62.2%) total number of prescriptions collected from inpatient department, Government Headquarters Hospital Ooty (GHQH) showed 147 DDIs (Table 2) where patients were followed up and assessed for clinically DDI and when frequency of administration was taken into consideration was not found clinically significant.

Demographics characteristic
The study showed that among the 402 prescriptions analyzed, 75.1% of drug interactions account for males and only 24.8% drug interactions account for females (Table 1). The grouping of the age categorization showed that as the age increases the chance of more number of drug interactions was observed.

Number of DDIs found in the prescription
The study showed that as the number of drugs prescribed increases the likelihood for a chance of an interaction.
Categorization of drug interactions based on mechanism

Categorization of drug interactions based on mechanism are shown in Table 5 and Figure 1, the study showed that prescriptions had more number of pharmacokinetic interactions than compared to pharmacodynamics and interactions due to unknown mechanisms.

Categorization of drug interactions based on severity

Categorization of drug interactions based on severity is as shown in Figure 2. The study showed more number of moderate (32%) interactions as compared to minor (18%) and major (49%) interactions.

Management required for the drug interactions documented

The types of management required for the clinically drug interactions are shown in Table 7. The study showed most of the interactions requires dose adjustment and monitoring for toxicity.

DISCUSSION

Clinically, potential DDI is a major concern for patients and health care professionals as most diseases require multiple drug regimens (Aline et al., 2015) and Raymond et al. (2008). The consequences of DDIs can range from untoward effects to drug-related morbidity and mortality (Zelalem et al., 2017) and (Rajender et al., 2007). Understanding the prevalence and patients at risk for clinically important DDIs at the visit level will be useful in minimizing medication-related problems and improving pharmaceutical care (Angeles and Sacramento, 2016) and (Catherin et al., 2003). Previous research has found that potential DDIs lead to adverse clinical outcomes, hospital admissions and emergency department (ED) visits (Becker and Kallewaard, 2007). Health care professionals' ability to recognize potential DDIs is important in reducing the risk of potential DDIs and their adverse consequences (Kulkarni et al., 2013; Yu et al., 2007 and Vijay et al., 2013).

A total of 1,066 prescriptions were analyzed during the study period from the government hospital where Number of Drug interactions per Hospitalised Patients found 102(69.4%), 28(19%), 17(11.66%) (Table 4) and selected four community pharmacies of which 402 (38%) prescriptions showed 462 DDIs. Prescriptions with single drug interactions was found to be high 53.73% (n=216) followed by two drug interactions 25.37% (n=102), three drug interactions 11.94% (n=48), four drug interactions 4.47% (n=18), six drug interactions 2.98% (n=12) and five drug interactions 1.6% (n=6). Age categorization revealed that adults (19-60 years) showed a greater number of interactions 58.17% (n=271) compared to pediatrics (≤18 years) 26.1% (n=121) and geriatrics (>60 years) 15.15% (n=70). The study prescriptions comprised 73.92% pharmacokinetic, 96% was pharmacodynamic.

Table 1. Demographic characteristics at four pharmacies.

| Characteristics | Number of drug Interactions | Percentage |
|-----------------|-----------------------------|------------|
| Gender          |                             |            |
| Male (307)      | 347                         | 75.1       |
| Female (95)     | 115                         | 24.8       |
| Total (402)     | 462                         | 100        |
| Age categorization (years) |                  |            |
| Paediatrics (<18) | 121                       | 26.1       |
| Adult (19-60)   | 271                         | 58.6       |
| Geriatrics (>60) | 70                         | 15.15      |
| Total           | 462                         | 100        |

Table 2. Demographic characteristics at hospitalized patients.

| Characteristics | Number of drug Interactions | Percentage |
|-----------------|-----------------------------|------------|
| Gender          |                             |            |
| Male (216)      | 98                          | 66.67      |
| Female (448)    | 49                          | 33.33      |
| Total (664)     | 147                         | 100        |
and 6.68% of interactions were due to unknown mechanisms 18% (Table 3). Statistical analysis did not show significant difference within the pharmacokinetic drug interactions, where drug interaction due to altered metabolism occurred most often 67.67%, followed by absorption related drug interaction (4.3%) and interaction related to distribution (1.07%). There were a greater number of major drug interactions (49%) which among of the potential drug -drug interactions occurred due to mostly frequently Responsible drugs for an Interaction as shown in (Table 6) than moderate (32%) and minor interactions were found among the prescriptions. The present study shows the prevalence of DDIs as 38% which was found similar to the results obtained from the
Table 3. Number of Drug Interactions per patients at four pharmacies.

| Number of drugs | Number of patients | Number of drug interactions (%) |
|-----------------|--------------------|---------------------------------|
| 2 - 5           | 254                | 297 (64)                        |
| 6 - 10          | 144                | 151 (32.54)                     |
| > 10            | 4                  | 14 (3.44)                       |

Table 4. Number of Drug Interactions per hospitalized patients at GHQH

| Number of drugs | Number of patients | Number of drug interactions (%) |
|-----------------|--------------------|---------------------------------|
| 2 - 5           | 209                | 102 (69.4)                      |
| 6 - 10          | 310                | 28 (19)                         |
| > 10            | 145                | 17 (11.66)                      |

Table 5. Categorization of drug interactions based on the mechanism.

| Categorization                        | No. of drug interaction | Percentage |
|---------------------------------------|--------------------------|------------|
| Absorption                            | 20                       | 4.3        |
| Distribution                          | 5                        | 1.07       |
| Pharmacokinetic Drug Interactions     |                          |            |
| Absorption                            | 20                       | 4.3        |
| Distribution                          | 5                        | 1.07       |
| Metabolism                            | 314                      | 67.67      |
| Excretion                             | 04                       | 0.86       |
| Total                                 | 343                      | 73.92      |
| Pharmacodynamic Drug Interactions     |                          |            |
| Total                                 | 88                       | 18.96      |
| Unknown Mechanism                     | 31                       | 6.68       |
| Total                                 | 462                      |            |

Table 6. Mostly frequently responsible drugs for an interaction.

| Class/Name of the drugs               | No. of interactions found (295) |
|---------------------------------------|---------------------------------|
| Antiplatlet                           | 24 (8.13%)                      |
| Clopidogrel                           | 19                              |
| Prasugrel                             | 05                              |
| NSAIDS                                | 33 (11.1%)                      |
| Aspirin                               | 14                              |
| Aceclofenac                           | 08                              |
| Diclofenac                            | 08                              |
| Ibuprofen                             | 03                              |
| Oral Hypoglycaemic                    | 27 (9.1%)                       |
| Metformin/Glimepiride                 | 24                              |
| Sitagliptin                           | 03                              |
| Calcium channel blockers              | 16 (5.4%)                       |
| Amlodipine                            | 11                              |
| Verapamil                             | 05                              |
| Antiarrhythmic                        | 12 (4.06%)                      |
| Amiodarone                            | 09                              |
| Quinidine                             | 03                              |
Table 6. Cont’d

| Category                | Count (%) |
|-------------------------|-----------|
| **PPIs**                | 14 (4.7%) |
| Rabeprazole             | 03        |
| Omeprazole              | 07        |
| Propanazone             | 04        |
| **Loop Diuretics**      | 21 (7.1%) |
| Furosemide              | 18        |
| Torsemide               | 03        |
| **Antifungal**          | 09 (3.0%) |
| Fluconazole             | 09        |
| **Anticonvulsant**      | 18 (6.1%) |
| Phenobarbital           | 08        |
| Clonazepam              | 06        |
| Carbamazepam            | 04        |
| **Antidepressant**      | 13 (4.4%) |
| Amitriptyline           | 07        |
| Citalopram              | 04        |
| Duloxetine              | 02        |
| **Corticosteroids**     | 21 (7.1%) |
| Prednisolone            | 12        |
| Dexamethasone           | 09        |
| **Vit. Supplemants**    | 09 (3.05%)|
| Niacin                  | 03        |
| Vit.B12                 | 02        |
| Vit.B                   | 04        |
| **Fluoroquinolones**    | 34 (11.52%)|
| Levofloxacin            | 16        |
| Norfloxacin             | 08        |
| Ofloxacin               | 06        |
| Ciprofloxacin           | 04        |
| **K+Sparring lactone**  | 09 (3.05%)|
| Spirolactone            | 09        |
| **Macrolide antibiotics** | 18 (6.1%) |
| Azithromycin            | 11        |
| Erythromycin            | 07        |
| **D2 Receptor blocker** | 17 (5.7%) |
| Domperidone             | 17        |
| **Total**               | 295 (100%)|

Studies conducted by Patel Jaskumar et al. (2016) and Kafeel et al. (2014) (Fantaye et al 2016). The underlying mechanism in the 462 interactions was found to be 73.92% of pharmacokinetic mechanism, 18.96% of pharmacodynamics mechanism and 6.68% involving unknown mechanisms. While assessing the severity of the drug interactions, 49% were major, 32% were moderate, and 19% of the interactions were minor. The study showed that majority of the interactions require dose adjustments and monitoring for signs and symptoms
for toxicity as compared to other methods of management which is similar results were obtained from the study (Murphy and Armstrong, 2009).

Conclusion

The present research study assessed the clinically potential DDIs in a hospital and community pharmacy prescriptions. The study analyzed that most of the interactions would be managed by dose adjustment, monitoring patients for signs and symptoms for toxicity and a long term need to follow up patients for clinically DDI. This study elaborates that the nature of clinically drug interaction is a complex process due to involvement of multiple mechanism and thus impossible to document all clinically significant DDIs.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENT

The authors acknowledge technical assistance from Government Hospital staffs and the Tanzania Commission for Science and Technology (COSTECH) for providing training to Authors on how to write Scientific Research Paper for publication in international journals. This training held in Bagamoyo from 25th to 27th November 2020, helped to improve the capacity of authors on how to draft the manuscripts, and responding to reviewers comments.

Table 7. Management requirements for the drug interactions documented.

| Management | Number of drug interactions (%) |
|------------|---------------------------------|
| Monitor for drug levels | 46 (9.9) |
| Dosage adjustment | 62 (13.4) |
| Monitor for electrolyte levels | 28 (6.0) |
| Avoid the combination | 37 (8.0) |
| Monitor for signs and symptoms | 55 (11.9) |
| Monitor for biochemical parameters | 39 (8.44) |
| Monitor for drug level and biochemical parameters | 7 (1.5) |
| Monitor for signs and symptoms and biochemical parameters | 28 (6.0) |
| Monitor for signs and symptoms and drug level | 12 (2.6) |
| Monitor for patient response | 17 (3.62) |
| Monitor for patient response and dose adjustment | 21 (4.54) |
| Dose titration | 15 (3.3) |
| Monitor for electrolyte and drug level | 05 (1.08) |
| Change dosing interval | 39 (8.44) |
| No management required | 51 (11.0) |

REFERENCES

Aline TR, Rebeca S, Silvia G (2015). Clinical relevancy and risks of potential drug–drug interactions in intensive therapy Saudi Pharmaceutical Journal 23(4):366-370.

Angeles FE, Sacramento DC (2016). Potential drug–drug interactions in hospitalised haematological patients. Journal of Oncology Pharmacy Practice 5(14):1-11.

Becker ML, Kallewaard M (2007). Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiology and Drug Safety 16(6):641-51.

Bruno H (2007). Determinants of drug drug interactions associated dispensing in community pharmacies in the Netherlands. Pharmacy world science 29(2):51-57.

David N, Juurlink Muhammad (2003). Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. Journal of American Medical Association 289(13).

Elena T, Manuela C, Vasco Pierl (2013). Prevalence of the Prescription of Potentially Interacting Drugs. International Journal of Clinical Pharmacy 8(10):7882-7887.

Fantaye T, Gebrehiwot T, Eskindeir A, Terefe T (2016). Potential drug–drug interactions among elderly patients admitted to medical ward of Ayder Referral Hospital, Northern Ethiopia: a cross sectional study. Biomedical central Journal 13(104):238-255.

Janchawee B (2005). Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand Journal of Clinical Pharmacy and Therapeutics 30(1):13-20.

Janja Jazbar, Igor Locatelli, Nejc Horvat, Mitja Kos (2017). Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study: Chair of Social Pharmacy, University of Ljubljana 42(3):14-25.

Jindal D, Sharma H, Karim S (2005). Drug interactions in prescriptions from selected Indian community pharmacies. Journal of Pharmacy Resolution 35:332.

Jorg I, Laura E, Marianne B, Rudolf B, Walter E, Haeferli. K, Hersberger E (2007). Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. European Journal Clinical Pharmacology 63(3):297-305.

Kafeel H, Rukh R, Qamar H, Bawany J, Jamshed M, Sheilkh R, Hanif T, Bokhari U, Jawaid W (2014). Possibility of Drug-Drug Interaction in Prescription Dispensed by Community and Hospital Pharmacy Pharmacoepidemiology and Pharmacy 5(5):401-407.

Kaushikbhai Suthar Umesh (2016) A study on Prevalence of Potential Drug Drug Interactions in Community Pharmacies of Mysore city:
International Journal of Research Studies in Biosciences 4(50):2349-0365.

Kennedy DT, Gossell WM, Hall J, Anglin-Brown B (2015). The prevalence of major potential drug-drug interactions at a University health centre pharmacy in Jamaica. Pharmacy Practice 13(4):601.

Kulkarni V, Bora SS, Sirisha S, Saji M, Sundaran S (2013). A study on drug–drug interactions through prescription analysis in a South Indian teaching hospital. Therapeutic advances in drug safety 4(4):141-146.

Lubinga SJ, Uwiduhaye E (2011) Potential drug-drug interactions in inpatient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors. African Health Sciences Journal 11(3):499-507.

Malone DC, Hutchins DS, Haupert H (2005). Assessment of potential drug–drug interactions with a prescription claims database. American Journal of Health System Pharmacy 62(19):1983-1991.

Mitja K (2017). Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study: Chair of Social Pharmacy, University of Ljubljana. Journal 7(14):58-78.

Murphy JE, Armstrong EP (2006). Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. Journal of Managed Care Pharmacy 12(5):383-389.

Patel Jaskumar N, Ansu AS, Jaidev K, Mit K, Suthar U (2016). A study on Prevalence of Potential Drug Drug Interactions in Community Pharmacies of Mysore city: International Journal of Research Studies in Biosciences 4(5):2349-0365.

Rajender A, Rebecca B, Anuradha A (2007). Clinically important potential drug-drug interactions in outpatient settings. Research in Social and Administrative Pharmacy 3(4):426-437.

Raymond L, Woosley D (2008). Potential Determinants of Prescribers’ Drug-Drug Interaction Knowledge. Research in Social and Administrative Pharmacy 4(4):355-366.

Truven Health Analytica IBM Micromedex Solutions (2016). Available from http://www.micromedexsolution.com-[Accessed on the Internet]

Vijay K, Sapineni S, Mohammed S, Siraj S (2013). A study on drug–drug interactions through prescription analysis in a South Indian teaching hospital. Journal of Therapeutics 4(4):141-146.

Vonbach P, Dubied A, Beer JH, Krähenbühl S (2007). Recognition and management of potential drug-drug interactions in patients on internal medicine wards. European Journal of Clinical Pharmacology 63(11):1075-1083.

Walter E, Haefeli K, Hersberger E (2007). Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland European Journal Clinical Pharmacology 63:297-305.

Yu K, Daniel CM, Jerome VDA, Grant HS, Edward PA, Mary B, Raymony L (2008). Potential interactions in inpatients treated at the Internal Medicine Ward of Tikur Anbessa Specialized Hospital Health Care and Patient Safety 9:71-76.

Zelaem T, Tesfaye T, Nedi S (2017). Potential drug–drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital health Care and Patient Safety 9:71-76.